Market Place
Sourcing Support
Takeda Receives EU Approval for FRUZAQLA
22 Jun 2024 //
PRESS RELEASE
FDA approves Taiho`s Lonsurf with bevacizumab for metastatic colorectal cancer
03 Aug 2023 //
ENDPTS
FDA Approves LONSURF in Combination With Bevacizumab for mCRC
02 Aug 2023 //
PR NEWSWIRE
Natco`s Generic Tipiracil HCL, Trifluridine Receives Approval in the U.S.
13 Jun 2023 //
FDA
Taiho Oncology & Servier Announce in New Engl& Journal pH 3 Data for (LONSURF®)
03 May 2023 //
BUSINESSWIRE
U.S. FDA Accepts for Priority Review Taiho Onc`s sNDA for Trifluridine/Tipiracil
18 Apr 2023 //
PR NEWSWIRE
Servier & Taiho Present Survival Data for LONSURF With Bevacizumab at 2023 ASCO
17 Jan 2023 //
BUSINESSWIRE
XBiotech Announces First Patient Enrolled French(INCA) Ph I/II/III Natrunix™
13 Oct 2022 //
GLOBENEWSWIRE
Drug Combination Meets Survival Endpoint in Ph III Pivotal Trial With RMCC
12 Sep 2022 //
BUSINESSWIRE
XBiotech Announces ANSM Approval, INSA funding for PII/III Study for Natrunix
28 Apr 2022 //
GLOBENEWSWIRE
NATCO Pharma launches Tipanat tablets for advanced colorectal, gastric cancer
23 Nov 2021 //
INDIAINFOLINE
Natco Pharma launches Tipanat tabs for colorectal and gastric cancer
18 Nov 2021 //
PHARMABIZ
Servier Phase III colorectal cancer trial fails to meet primary endpoint
21 Oct 2021 //
PHARMAFILE
National Comprehensive Cancer Network® Provides Updates on Use of LONSURF®
04 Feb 2021 //
PRNNEWSWIRE
Servier adds EU approval for Lonsurf in gastric cancer
06 Sep 2019 //
THEPHARMALETTER
LONSURF®trifluridine/tipiracil Receives Marketing Authorization EU for Patient
05 Sep 2019 //
BUSINESSWIRE
FDA Approves Taiho Oncology`s LONSURF® (trifluridine/tipiracil)
25 Feb 2019 //
PR NEWSWIRE
Servier and Taiho Oncology Present Latest LONSURF® (trifluridine/tipiracil) Data
18 Jan 2019 //
BUSINESSWIRE
Taiho Oncology & Servier to Present Data on LONSURF® (trifluridine & tipiracil)
14 Jun 2018 //
PR NEWSWIRE
Taiho Oncology Eliminates Co-Pays for Many of the Patients Treated with LONSURF®
07 Jun 2018 //
PR NEWSWIRE
Taiho Pharma Canada, Inc. announces Health Canada approval of LONSURF®
06 Mar 2018 //
NEWSWIRE
Hi-Tech Pharmacal’s Generic Trifluridine Receives Approval In US
31 Jul 2017 //
FDA
Xarelto and Eylea continue to dominate Bayer`s pharma sales
24 Feb 2017 //
PMLIVE
Bayer`s struggling Stivarga moves closer to liver-cancer lifeline
04 Jan 2017 //
FIERCE PHARMA
Servier’s Lonsurf backed for NHS use
25 Aug 2016 //
PHARMATIMES
Servier`s Lonsurf approved in Europe for colorectal cancer
27 Apr 2016 //
PHARMA TIMES
Opdivo backed for two new uses by CHMP
29 Feb 2016 //
PM LIVE
CHMP Issues Opinion for LONSURF for Refractory Metastatic Colorectal Cancer
29 Feb 2016 //
PR NEWSWIRE
Taiho Oncology, Inc Announces Comprehensive Access Support Program for LONSURF
29 Sep 2015 //
PR NEWS WIRE
Taiho, Servier sign exclusive license agreement to develop and commercialize TAS-102 drug
15 Jun 2015 //
NEWS MEDICAL
Taiho Submits Colorectal Cancer Drug In Europe
03 Mar 2015 //
PHARMATIMES
